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Cleavage of huntingtin (htt) has been character-
ized in vitro, and accumulation of caspase
cleavage fragments represents an early patho-
logical change in brains of Huntington’s disease
(HD) patients. However, the relationship be-
tween htt proteolysis and the pathogenesis of
HD is unknown. To determine whether caspase
cleavage of htt is a key event in the neuronal dys-
function and selective neurodegeneration in
HD, we generated YAC mice expressing cas-
pase-3- and caspase-6-resistant mutant htt.
Mice expressing mutant htt, resistant to cleav-
age by caspase-6 but not caspase-3, maintain
normal neuronal function and do not develop
striatal neurodegeneration. Furthermore, cas-
pase-6-resistant mutant htt mice are protected
against neurotoxicity induced by multiple
stressors including NMDA, quinolinic acid (QA),
and staurosporine. These results are consistent
with proteolysis of htt at the caspase-6 cleavage
site being an important event in mediating neu-
ronal dysfunction and neurodegeneration and
highlight the significant role of htt proteolysis
and excitotoxicity in HD.
INTRODUCTION
Huntington’s disease (HD), a neurodegenerative disorder
characterized by progressive deterioration of cognitive
and motor functions, is caused by an expansion of a trinu-
cleotide (CAG) repeat encoding glutamine in the N termi-
nus of huntingtin (htt). Polyglutamine expansion resultsin selective loss of GABAergic medium spiny striatal neu-
rons as well as glutamatergic cortical neurons that project
to the striatum (Albin et al., 1990, 1992). A neuropatholog-
ical hallmark in human HD and mouse models is the intra-
cellular accumulation of N-terminal htt fragments (Gute-
kunst et al., 1999; Kim et al., 2001), suggesting that
aberrant htt proteolysis and/or dysfunctional clearance
of htt fragments may underlie the neuropathology in HD.
Several proteases, including caspases, calpains, and
aspartyl endopeptidases, cleave htt within the N-terminal
region (Wellington et al., 1998; Lunkes et al., 2002; Gafni
et al., 2004), and in vitro studies have demonstrated that
expanded N-terminal htt fragments have enhanced cyto-
toxicity (Hackam et al., 1998). Furthermore, although
some HD mouse models expressing truncated mutant
htt (mhtt) demonstrate behavioral deficits and neuronal in-
clusions (Davies et al., 1997; Schilling et al., 1999), in vivo
expression of an expanded N-terminal htt fragment con-
taining exons 1 and 2 (the shortstop model) does not result
in a behavioral or neurodegenerative phenotype (Slow
et al., 2005), demonstrating that N-terminal htt fragments
do not per se invariably result in pathology. In addition,
while several studies have shown that translocation of
htt to the nucleus is associated with increased toxicity in
vitro and neuropathology in vivo (Wheeler et al., 2000;
Wellington et al., 2002), the shortstop mouse exhibits
widespread diffuse nuclear htt but no neurotoxicity, sug-
gesting either that N-terminal fragments containing the
mutation alone are insufficient to cause the disease or
that a specific nuclear htt fragment is critical for the neuro-
nal degeneration in HD. In the YAC128 model, which ex-
presses full-length mhtt, nuclear localization of htt frag-
ments occurs earliest and to the greatest extent in the
striatum, the region most affected in HD (Van Raamsdonk
et al., 2005a).
htt is cleaved by caspase-3 and -6 in vitro, and cas-
pase-3-cleaved htt fragments are detectable in HD brainCell 125, 1179–1191, June 16, 2006 ª2006 Elsevier Inc. 1179
prior to the clinical onset (Wellington et al., 1998, 2002). In
addition, site-directed mutagenesis of all five caspase
cleavage sites in mhtt blocks cytotoxicity in vitro (Welling-
ton et al., 2000). These observations raise the questions of
whether the caspase-specific htt fragments are important
in the pathogenesis of HD and whether inhibiting caspase
cleavage of mhtt may be protective in vivo.
We have previously developed a YAC model for HD that
displays age- and CAG-dependent phenotypes that reca-
pitulate many features of the human disease. Specifically,
enhanced susceptibility to excitotoxic stress, cleavage
and nuclear localization of htt, and cognitive dysfunction
are followed by motor deficits and selective striatal degen-
eration (Slow et al., 2003; Van Raamsdonk et al., 2005a,
2005b; Graham et al., 2005), recapitulating many aspects
of human HD.
To determine whether caspase cleavage of mhtt repre-
sents a primary event in the pathogenesis of HD in vivo, we
generated YAC mice expressing expanded htt containing
selective mutations of the caspase-3 and caspase-6
cleavage sites.
Here we report that cleavage at the 586 amino acid (aa)
caspase-6 site in mhtt is required for the development of
the characteristic behavioral and neuropathological fea-
tures of HD. Selective elimination of the caspase-6, but
not caspase-3, cleavage site in mhtt is sufficient to provide
protection from neuronal dysfunction and neurodegenera-
tion in vivo. These data suggest that specific mhtt frag-
ments are required to initiate a toxic cycle that leads to
neuronal dysfunction and the neuropathological abnor-
malities in HD. Our results are consistent with in vivo pro-
teolytic cleavage of mhtt at the caspase-6 cleavage site
being a crucial and rate-limiting event in the pathogenesis
of HD and suggest that preventing caspase-6 cleavage of
htt may be of therapeutic interest.
RESULTS
Generation of Caspase-Resistant Lines
The caspase sites in the human HD gene are located in
exons 12 and 13. Exon 12 encodes htt aa 470 to 583
and contains two active caspase-3 sites at positions 513
(510DSVD513) and 552 (549DLND552), as well as one silent
caspase-3 site at position 530 (527DEED530) (Wellington
et al., 1998). Exon 13 encodes htt aa 584 to 624 and con-
tains the active caspase-6 site at position 586 (583IVLD586)
as well as another silent caspase-3 site at position 589
(586DGTD589) (Wellington et al., 2000). Specific mutations
of the P1 aspartate at positions 513 and 552 would be ex-
pected to generate C3R htt, and a mutation at residue 586
would be expected to generate C6R htt. To ensure that the
silent caspase-3 sites would be unable to be cryptically
activated in vivo, we also mutagenized their P1 aspartate
residues.
The mutagenized exons were introduced by homolo-
gous recombination in yeast into YAC353G6 (see the Sup-
plemental Experimental Procedures and Figure S1 in the
Supplemental Data available with this article online) and1180 Cell 125, 1179–1191, June 16, 2006 ª2006 Elsevier Inc.verified by Southern blot and PCR (data not shown). Ver-
ified caspase-resistant (CR) YACs were purified and mi-
croinjected into FVB/N pronuclei (Hodgson et al., 1999).
Founders were confirmed by a five-point PCR screen (Fig-
ure S2) and by sequencing (data not shown).
Using this strategy, we generated two independent
mouse lines expressing human mhtt resistant to both cas-
pase-3 and -6 known as caspase quint resistant (CQR)
lines 24 (CQR24) and 26 (CQR26). We also developed
two independent lines selectively resistant to caspase-3
(C3R8 and C3R9) and two resistant to caspase-6 (C6R7
and C6R13).
Characterization of CAG Size and Transgene
Expression Levels
The phenotype of HD in YAC128 mice is influenced by
levels of expression of mhtt (Graham et al., 2005); there-
fore, it is essential to control not only for CAG size but
also for levels of transgene expression.
PCR-mediated CAG sizing was used to ensure equiva-
lent CAG sizes among caspase-cleavable and CR lines
(Figure 1A). Lines HD53, HD54, CQR24, C3R8, and
C3R9 all contain 120 CAG repeats. Lines C6R7 and
C6R13 each have 133 CAGs, and CQR26 contains two
CAG sizes of 120 and 83. Thus, all of the CR lines have
CAG sizes at least as large as the control YAC lines.
Quantitative mRNA and Western blotting was then used
to match transgene expression in each CR murine brain
tissue to the most appropriate YAC128 line (n = 3, age
matched). htt expression levels in CQR24 and CQR26 (up-
per allele) were found to be equivalent to HD54 (Figures 1B
and 1C). The CQR26 mice display two distinct protein
sizes on Western blots (Figure 1C), which was accounted
for by a spontaneous contraction of the glutamine tract in
one copy of the YAC in CQR26 animals. htt expression
analysis in C3R8 and C3R9 demonstrates that both of
these lines also express human mhtt at levels equivalent
to HD54 (Figures 1B and 1C), whereas mhtt levels in
C6R7 and C6R13 mice are similar to the previously de-
scribed HD53 mice and higher than HD55 (Figures 1B
and 1C). The different forms of mhtt are expressed simi-
larly in different regions of CR and caspase-cleavable
(YAC128) murine brain (Figure S3).
Caspase-Resistant htt Expressed in CR Mice
Is Resistant to Caspase Proteolysis
Western blotting shows that caspase-3 and -6 do not
cleave htt in CQR24 or CQR26 brain lysates (Figure 2A),
verifying that the mutations introduced into CQR mhtt
block cleavage of mhtt by caspases-3 and -6. In contrast,
HD54 brain lysates give rise to the expected htt caspase
fragments (70 kDa for endogenous and 98 kDa for mhtt)
(Figure 2A).
Western blotting demonstrates that caspase-3 cleaves
only endogenous htt in brain lysates prepared from C3R8
and C3R9 mice (Figure 2B). In contrast, caspase-3 treat-
ment of lysates prepared from HD54 brain generated the
expected 70 kDa and 98 kDa htt fragments representing
Figure 1. Characterization of Caspase-Resistant and Control YAC Lines
(A) Agarose gel showing PCR for the CAG tract of transgenic htt in YAC 18, 46, 72, and 128 (HD53 and 54) lines (described previously, Hodgson et al.,
1996; Graham et al., 2005) and CQR24, CQR26, C3R8, C3R9, C6R7, and C6R13. Wild-type is included as a negative control. Lines HD53, HD54,
CQR24, C3R8, and C3R9 all display a 120 CAG repeat size. Lines C6R7 and C6R13 have 133 CAG repeats, and CQR26 contains two CAG sizes
of 120 and 83.
(B) Real-time quantitative RT-PCR showing mRNA transgene levels in CR murine brain compared against YAC128 (n = 3). mhtt levels in CQR24 are
equivalent to HD54. CQR26 demonstrates approximate doubling of mhtt levels due to contribution from two alleles (left panel). Transgene levels in
C3R8 and C3R9 are equivalent to HD54 (middle panel). mhtt expression levels in C6R7 and C6R13 are similar to HD53 and higher than HD55 (right
panel).
(C) High-resolution Western blot of CR and YAC128 brain tissue probed with BKP1 htt antibody (upper panels). mhtt level of upper allele in CQR26
(120 CAG) is similar to HD54. Quantification of mhtt protein levels in CR and YAC128 murine brain (lower panels) correlates with mRNA levels. Trans-
gene protein levels have been normalized to endogenous htt. Mean measurements and densitometric ratios of mutant htt/endogenous htt are ±SD
(n = 3).the endogenous and mhtt protein. Incubation of C3R ly-
sates with caspase-6 results in the expected fragments
from endogenous and mhtt, demonstrating that C3R
mhtt is only resistant to cleavage by caspase-3
(Figure 2D).
Conversely, treatment of brain lysates from HD53 with
caspase-6 generated the expected caspase-6 fragments
from transgenic (115 kDa) and endogenous htt (90 kDa)
(Figure 2C). As expected, only endogenous htt is cleaved
by caspase-6 in brain lysates from C6R7 and C6R13 mice
(Figure 2C). This caspase-6 mhtt fragment is detected in
vivo in HD53, HD54, and C3R brain lysates, while it is ab-
sent in C6R brain lysates (C6R7 and C6R13, Figure 2E).
Assessment of the toxicity of the 586 aa N-terminal mhttfragment in vitro demonstrates that it is more toxic than
the caspase-3 513 aa or 552 aa mhtt fragments in trans-
fected N2A cells exposed to staurosporine (n = 3, ANOVA
p = 0.0015; Figure S4). Incubation of C6R brain lysates
with caspase-3 results in caspase-3 endogenous and
mhtt fragments, demonstrating that C6R mhtt is selec-
tively resistant to cleavage by caspase-6 (Figure 2F).
This is further substantiated in vivo using the caspase-3
neo-epitope antibody (htt552) (Wellington et al., 2002).
htt552 immunostaining of brain slices from wild-type
(wt), HD53, and C6R mice demonstrates the presence of
htt cleaved at aa 552 predominantly in the cytoplasm
and processes of a subset of striatal neurons in all mice
irrespective of genotype (Figure 2G).Cell 125, 1179–1191, June 16, 2006 ª2006 Elsevier Inc. 1181
Figure 2. Caspase-Resistant Huntingtin Expressed in the Transgenic Mice Is Resistant to Specific Caspase Cleavage
(A) Whole brain lysates were subject to digestion with the respective caspase. Western blotting demonstrates that caspase-3 and -6 only cleave mhtt
(98 kDa fragment, arrow) in HD54; the 70 kDa band (present in HD54, CQR24, and CQR26) represents endogenous htt.
(B) Caspase-3 cleaves mhtt only in HD54 and not C3R murine brain.
(C) Caspase-6 cleaves mhtt selectively in HD53, and not C6R7 and C6R13, murine brain, resulting in a 115 kDa fragment (arrow); the 90 kDa band
represents cleaved endogenous htt.
(D) Caspase-6 cleaves mhtt (115 kDa fragment) and endogenous htt (90 kDa) in C3R mice.
(E) Western blot probed with 1C2 antibody demonstrates that a mutant htt fragment (arrow), running at the same size as the mutant htt fragment gen-
erated by caspase-6 cleavage (lane 1), is observed in HD53 cortex and striatum lysates (lane 2); this band is not present in either of the C6R cortex or
striatum lysates (C6R7, lane 3 and C6R13, lane 4). The caspase-6 mhtt fragment is also observed in HD54 and C3R cortex lysates (lanes 6 and 7).
Actin is included as a loading control.
(F) Caspase-3 cleaves mhtt in C6R mice, resulting in a 98 kDa fragment; the 70 kDa band represents cleaved endogenous htt.
(G) htt552 immunostaining of striatum from wt, HD53, and C6R mice shows the presence of htt cleaved at aa 552 predominantly in the cytoplasm and
processes of a subset of striatal neurons. C3R mice on an htt knockout background (C3R/) are included as a negative control. Scale bar = 10 mm. All
Western blots were probed with BKP1 except where noted.Caspase-Resistant Mutant htt Retains
Developmental Functions In Vivo
Transgenic htt expressed from a YAC rescues the embry-
onic lethality of htt-deficient animals (Hodgson et al.,1182 Cell 125, 1179–1191, June 16, 2006 ª2006 Elsevier Inc.1996). We observe rescue of embryonic lethality of htt-
knockout mice with a similar efficiency in CR YAC lines
and YAC mice expressing caspase-cleavable htt, demon-
strating that mutagenesis of the caspase sites in mhtt
does not impair htt function in vivo during development
(Table S1). In YAC mice expressing low levels of mhtt
(HD54 and C3R9), only partial rescue is observed, consis-
tent with observations that developmental viability re-
quires a threshold level of htt expression (Auerbach
et al., 2001).
Inhibition of Caspase Cleavage of Huntingtin
Prevents Neurodegeneration In Vivo
Significant brain atrophy and loss of striatal volume have
previously been reported in HD53 mice by 9 months
(Slow et al., 2003), in HD55 by 12 months, and in the
lower-expressing HD54 line by 18 months (Graham
et al., 2005). First, we measured brain weights and striatal
volumes in CQR and HD54 mice at 18 months (n = 8). No
reduction in brain weight is observed for either the CQR24
or the CQR26 line compared to wt mice (CQR (pooled) =
0.39 ± 0.01 g, wt = 0.40 ± 0.02 g, p = 0.14; Figure 3A).
As expected, HD54 brain weights are significantly lower
than wt controls at 18 months (HD54 = 0.37 ± 0.01 g,
p = 0.02). Similarly, striatal volume is reduced by 9% in
HD54 mice relative to wt controls (HD54 = 11.9 ± 0.65 mm3,
wt = 13.2 ± 0.96 mm3, p = 0.03; Figure 3A). By contrast,
CQR24 and CQR26 mice do not exhibit any significant
reduction in striatal volume at 18 months compared to
wt mice (CQR (pooled) = 12.6 ± 0.74 mm3, p = 0.22). These
observations suggest that caspase cleavage of mhtt is
required for striatal volume loss.
To distinguish whether caspase-3 or -6 cleavage of
mhtt, or both, is critical for mediating striatal atrophy, we
next evaluated brain weights and striatal volumes in the
C3R lines relative to the appropriate control line HD54
and wt mice (n = 8). At 18 months, brain weight and striatal
volumes in the C3R lines (pooled) are indistinguishable
from HD54 (brain weight C3R = 0.37 ± 0.02 g, HD54 =
0.37 ± 0.01 g, p = 0.75; striatal volume C3R = 11.8 ±
0.90 mm3, HD54 = 11.9 ± 0.65 mm3, p = 0.84;
Figure 3B) and significantly less than wt controls (brain
weight wt = 0.40 ± 0.02 g, p = 0.002; striatal volume
wt = 13.2 ± 0.96 mm3, p = 0.003). These findings demon-
strate that preventing caspase-3 cleavage of mhtt pro-
vides no protection from striatal atrophy in vivo. Notably,
mice expressing C3R mhtt still generate caspase-6 frag-
ments of mhtt (Figures 2D and 2E).
We next evaluated whether caspase-6 cleavage of mhtt
influences brain weight and striatal volume in vivo. As ex-
pected (Graham et al., 2005), HD53 brain weight and stria-
tal volume are reduced compared to wt controls at 18
months (n = 8, brain weight HD53 = 0.35 ± 0.01 g, wt =
0.38 ± 0.02 g, p = 0.04; striatal volume HD53 = 10.9 ±
0.40 mm3, wt = 12.9 ± 0.42 mm3, p < 0.0001; Figure 3C).
By contrast, brain weight and striatal volume from C6R7
and C6R13 lines (pooled) are indistinguishable from wt
controls (n = 8, brain weight C6R = 0.38 ± 0.03 g, C6R ver-
sus wt: p = 0.61; striatal volume C6R = 12.3 ± 0.83 mm3,
C6R versus wt: p = 0.10), and striatal volume is signifi-
cantly increased relative to HD53 (p < 0.01, ANOVA p =
0.0004; Figure 3C). These data demonstrate that selectiveFigure 3. Inhibition of Caspase Cleavage of Mutant Hunting-
tin Prevents Neurodegeneration In Vivo
(A) Brain weight and striatal volume at 18 months in wt, HD54, and CQR
mice (n = 8). Brain weight and striatal volume are preserved in CQR
mice and are similar to wt (p = 0.14 and p = 0.22, respectively). In con-
trast, HD54 brain weight and striatal volume are significantly reduced
versus wt (p = 0.02 and p = 0.03, respectively).
(B) Brain weight and striatal volume in C3R lines (pooled) are indistin-
guishable from HD54 (p = 0.75 and p = 0.84, respectively) and are sig-
nificantly less than wt controls (p = 0.002 and p = 0.003, respectively;
n = 8).
(C) HD53 brain weight and striatal volume are significantly reduced
compared to wt controls (p = 0.04 and p < 0.0001, respectively). By
contrast, brain weight and striatal volume in C6R lines (pooled) are
indistinguishable from wt (p = 0.61 and p = 0.10, respectively), and
striatal volume is significantly increased versus HD53 at 18 months
of age (p < 0.01, ANOVA p = 0.0004; n = 8).
(D) Striatal volume (left panel) and neuronal profiles (right panel) at 12
months in wt, HD53, and C6R mice (n = 7). HD53 mice demonstrate
significant striatal volume and neuronal loss at 12 months (p < 0.001
and p < 0.05, respectively). The C6R mice show preserved striatal vol-
ume and no neuronal loss and are significantly different from HD53
(striatal volume C6R versus wt: p = 0.57, C6R versus HD53: p <
0.001, ANOVA p = 0.0002; neuronal counts C6R versus wt: p = 0.74,
C6R versus HD53: p = 0.02). Mean measurements are given ±SD.
*p < 0.05; **p < 0.01; ***p < 0.001.Cell 125, 1179–1191, June 16, 2006 ª2006 Elsevier Inc. 1183
Figure 4. Inhibition of Caspase Cleavage of Mutant Huntingtin Protects against Neuronal Dysfunction
(A) HD53 mice show a significant deficit on the rotarod at 2 months of age compared to wt (p < 0.01). In contrast, C6R7 mice perform similar to wt and
are significantly different from HD53 mice at 2 (p < 0.05), 6 (p < 0.05), and 8 (p < 0.05) months of age (ANOVA p < 0.0001; n = 9).
(B) HD53 mice demonstrate a progressive hypokinetic phenotype commencing at 4 months of age (p < 0.01) compared to wt during a 30 min open-
field trial. C6R7 mice display activity levels indistinguishable from wt at all time points tested and are significantly different from HD53 at 6 (p < 0.05), 8
(p < 0.01), and 10 (p < 0.01) months of age (ANOVA p < 0.0001; n = 9). Time on rotarod (s) and activity are mean value ±SEM. *p < 0.05; **p < 0.01; ***p <
0.001.mutation of the caspase-6 site in mhtt is sufficient to pro-
tect mice from the neurotoxic effects of polyglutamine ex-
pansion and striatal volume loss in vivo.
We then assessed striatal volume and neuronal counts
in C6R mice compared to HD53 animals at 12 months
(n = 7). As expected (Slow et al., 2003), HD53 mice demon-
strate significant striatal volume and neuronal loss at 12
months (striatal volume HD53 = 11.0 ± 0.74 mm3, wt =
12.6 ± 0.84 mm3, p < 0.001; neuronal counts HD53 =
[12.4 ± 0.89] 3 105, wt = [13.7 ± 1.31] 3 105, p < 0.05;
Figure 3D). C6R mice exhibit preserved striatal volume
and no neuronal loss at 12 months and are significantly
different from HD53 mice (striatal volume C6R = 12.4 ±
0.46 mm3, C6R versus wt: p = 0.57, C6R versus HD53:
p < 0.001, ANOVA p = 0.0002; neuronal counts C6R =
[13.9 ± 1.25] 3 105, C6R versus wt: p = 0.74, C6R versus
HD53: p = 0.02; Figure 3D). Mice expressing C6R mhtt still
generate a caspase-3 fragment of mhtt (Figures 2F and
2G), which clearly has no neurotoxicity in vivo. These
observations suggest that selective cleavage of mhtt by1184 Cell 125, 1179–1191, June 16, 2006 ª2006 Elsevier Inc.caspase-6, but not caspase-3, is a critical step in develop-
ment of striatal atrophy.
Inhibiting Caspase Cleavage of Mutant Huntingtin
Protects against Motor Dysfunction
HD53 and HD55 mice develop cognitive and motor abnor-
malities that recapitulate many clinical features of HD (Van
Raamsdonk et al., 2005b; Graham et al., 2005). To inves-
tigate motor dysfunction, wt, HD53, and C6R mice (sex
and weight matched, n = 9) were assessed using an accel-
erating rotarod. HD53 mice show a significant deficit on
the rotarod at 2 months (p < 0.01; Figure 4A). By contrast,
C6R mice perform as well as wt animals up to and includ-
ing 10 months and perform better than HD53 mice at 2 (p <
0.05), 6 (p < 0.05), and 8 (p < 0.05) months (ANOVA p <
0.0001; Figure 4A). As the HD53 mice showed a deficit
at the start of the behavior trial, an additional cohort was
assessed at 1 month to determine whether baseline ro-
tarod performance is similar between genotypes. At 1
month, all mice perform similarly (Figure S5).
The HD53 mice demonstrate a progressive hypokinetic
phenotype commencing at 4 months compared to wt dur-
ing a 30 min open-field trial (p < 0.01; Figure 4B). In con-
trast to the HD53 mice, the C6R mice display activity
levels indistinguishable from wt at all times tested. Fur-
thermore, the C6R mice perform better than HD53 mice
at 6 (p < 0.05), 8 (p < 0.01), and 10 (p < 0.01) months
(ANOVA p < 0.0001; Figure 4B). These results demon-
strate that preventing the generation of the caspase-6
cleavage fragment of mhtt is sufficient to prevent the
motor dysfunction observed in the YAC model.
Altered Nuclear Translocation of Huntingtin
in the Striatum of C6R Mice
Nuclear translocation of htt and formation of inclusions are
neuropathological hallmarks of HD (Davies et al., 1997;
Gutekunst et al., 1999; Slow et al., 2005). To investigate
whether inhibiting caspase-6 cleavage of mhtt alters nu-
clear translocation of htt, brain sections from wt, CR,
and YAC128 mice were immunostained with EM48, an an-
tibody that recognizes N-terminal htt fragments and is
highly specific for inclusions (Gutekunst et al., 1999).
EM48 immunoreactivity is not observed in wt striatum at
any time point. However, diffuse nuclear htt is observed at
3 months in the striatum of HD53 mice (Figure 5A). Nuclear
htt increases with age, and by 12 months, the majority of
striatal neurons demonstrate extensive EM48 staining
(Figure 5C). In contrast, nuclear localization of mhtt is de-
layed in the C6R lines, with just detectable levels in the
striatum at 9 months (Figure 5B), similar to HD53 striatum
at 2 months (Van Raamsdonk et al., 2005a). Between 9
and 12 months, there is an increase in nuclear htt in the
striatum of C6R mice, suggesting that other proteases
are activated and generate htt fragments not associated
with pathology (Figures 5B and 5C).
Low levels of diffuse nuclear htt are observed in HD54
and C3R lines at 18 months (Figure 5D). However, in sharp
contrast, both CQR lines demonstrate barely detectable
levels of EM48 staining at 18 months (Figure 5E), consis-
tent with the delay in nuclear htt observed in the C6R lines.
This evidence suggests that nuclear translocation of the
caspase-6 fragment of mhtt represents an early neuro-
pathological event in the YAC128 model of HD.
C6R Mice Are Resistant to Excitotoxicity
Overactivation of glutamate receptors has been consid-
ered a fundamental underlying mechanism in the early
stages of HD (Beal et al., 1986; Albin et al., 1990; Levine
et al., 1999; Zeron et al., 2002). We have demonstrated en-
hanced susceptibility to glutamate- and NMDAR-medi-
ated excitotoxicity in neonatal medium spiny neurons
(MSNs) from multiple YAC lines (Zeron et al., 2002; Gra-
ham et al., 2005). Conversely, MSNs overexpressing htt
with a normal CAG size (YAC18) show notably less cell
death than wt cultures upon NMDA treatment (Leavitt
et al., 2006), suggesting that htt mediates neuroprotection
by blocking excitotoxic cell death.We next assessed vulnerability to NMDAR-mediated ex-
citotoxicity in primary neonatal MSNs from wt, HD, and CR
pups. To be able to pool striata, we first generated homo-
zygous YAC128 (HD55; described in Graham et al., 2005)
and CR lines that were matched for equivalent mhtt protein
levels (Figure 6A). HD55+/mice express mhtt levels sim-
ilar to C3R (C3R8)+/+ and CQR (CQR24)+/+ mice and were
used as the YAC128 control line for the NMDA experiment.
HD55+/+ mice express levels of mhtt similar to C6R
(C6R7)+/ mice and were used as the YAC128 control
for the NMDA and staurosporine experiment. These pri-
mary striatal cultures contain a high level of MSNs as de-
fined by morphology and DARPP-32 staining (>85%) and
low levels of glia (<10%) (Shehadeh et al., 2005).
Protection from NMDAR-mediated excitotoxic death is
observed in MSNs that express CQR mhtt compared with
Figure 5. Delayed Nuclear Translocation of Huntingtin in the
Striatum of C6R Mice
(A–C) EM48 staining in the striatum of HD53 at 3 months shows clear
diffuse nuclear htt with no inclusions (A). No EM48 immunoreactivity is
observed in wt striatum at any time point. In line HD53, the level of nu-
clear htt increases with age, and by 12 months, the majority of striatal
neurons demonstrate extensive EM48 staining (C). In contrast, nuclear
localization of mhtt is delayed in the C6R lines, with just detectable
levels in the striatum at 9 months (B). Between 9 and 12 months, there
is a significant increase in nuclear htt in the striatum of C6R mice (C).
(D) EM48 staining in the striatum of HD54 and C3R mice at 18 months
shows clear diffuse nuclear htt.
(E) In contrast, nuclear localization of htt is delayed in the CQR lines,
with barely detectable levels in the striatum at 18 months. Scale
bars = 10 mm; n = 3.Cell 125, 1179–1191, June 16, 2006 ª2006 Elsevier Inc. 1185
Figure 6. Caspase Cleavage of Mutant Huntingtin Influences Susceptibility to Excitotoxicity
(A) YAC128 and CR lines were matched for equivalent mhtt protein levels using endogenous htt as control. Western blots of murine brain lysates from
heterozygous and homozygous YAC128 and CR mice probed with BKP1 are shown.
(B) MSNs from CQR striata demonstrate a decrease in cell death post-NMDA application versus HD55 (p < 0.001) and wt (p < 0.05).
(C) MSNs from C3R striata demonstrate an increase in susceptibility to NMDAR-mediated excitotoxicity versus wt (p < 0.01) and a similar level of cell
death versus HD55 (p > 0.05) post-NMDA treatment.
(D) MSNs from C6R striata show protection from NMDAR-mediated excitotoxicity with a decrease in cell death versus wt (p < 0.05) and HD55 (p <
0.001).
(E) Intrastriatal injection of quinolinic acid (QA) in 3-month-old mice (n = 6) reveals that virtually no fluorojade-positive cells are present in coronal sec-
tions of C6R brain. In contrast, in YAC128 (HD55) brain, a large area of the striatum is fluorojade positive, significantly larger in size compared to the
C6R (p < 0.0001) and wt (<0.05) lesion volume. Lesion volume is ±SEM.
(F) C6R mhtt protects against staurosporine-induced apoptotic cell death. YAC128 (HD55) MSNs are more vulnerable to staurosporine (10 mM) me-
diated death compared to wt MSNs (p < 0.05), while YAC18 MSNs demonstrate neuroprotection and reduced cell death compared to wt (p < 0.001).
Notably, MSNs expressing C6R mhtt are less susceptible to staurosporine-mediated cell death than wt (p < 0.001) and display a level of cell death
similar to MSNs overexpressing neuroprotective wt htt (YAC18 versus C6R p > 0.05) (ANOVA p < 0.0001). Mean percent apoptotic cells is given ±SD;
n = 3. *p < 0.05; **p < 0.01; ***p < 0.001.1186 Cell 125, 1179–1191, June 16, 2006 ª2006 Elsevier Inc.
HD55 (CQR = 2.6 ± 1.2, HD55 = 27.9 ± 6.1, p < 0.001) and
wt (wt = 8.6 ± 3.5, p < 0.05, ANOVA p = 0.0007; Figure 6B).
In contrast, MSNs expressing C3R mhtt exhibit increased
susceptibility to NMDA compared to wt (C3R = 26.8 ± 1.1,
wt = 8.6 ± 3.5, p < 0.01) and a level of vulnerability similar
to HD55 neurons (HD55 = 27.9 ± 6.1, p > 0.05, ANOVA p =
0.001; Figure 6C). Furthermore, C6R neurons are pro-
tected against NMDAR-mediated excitotoxicity com-
pared to HD55 (C6R = 2.4 ± 0.73, HD55 = 37.2 ± 7.7,
p < 0.001) and wt (wt = 8.6 ± 3.4, p < 0.05, ANOVA p =
0.0003; Figure 6D). To confirm that protection was due
to NMDAR activation, we also treated MSNs with
MK801 (20 mM), a NMDAR antagonist, in addition to 500
mM NMDA. Under these conditions, cell death was re-
duced to baseline conditions in all cultures (Figures 6B–
6D). These data demonstrate that MSNs expressing
CQR or C6R mhtt are no longer susceptible to NMDAR-
mediated toxicity as seen in MSNs expressing caspase-
cleavable (HD55) or C3R mhtt. Primary MSNs expressing
CQR or C6R mhtt demonstrate less NMDAR-mediated
apoptotic death than wt neurons, suggesting that inhibit-
ing caspase-6 cleavage of mhtt converts a neurotoxic
species into one that is neuroprotective.
To determine whether the resistance to excitotoxicity is
also observed in vivo, we next examined susceptibility to
quinolinic acid (QA) mediated neurotoxicity in 3-month-
old wt, HD55, and C6R mice. HD55 animals show en-
hanced lesion size compared to either C6R (HD55 = 1.9 ±
0.28 mm3, C6R = 0.17 ± 0.08 mm3, p < 0.0001) or wt
mice (wt = 0.91 ± 0.25 mm3, p < 0.05, ANOVA p <
0.0001; Figure 6E). In contrast, C6R mice exhibit reduced
lesion volume even compared to wt mice (p < 0.05), show-
ing that C6R htt protects from acute excitotoxicity despite
the presence of an expanded polyglutamine tract.
We also assessed cell death upon exposure to other ap-
optotic stimuli including staurosporine. As shown previ-
ously (Shehadeh et al., 2005), HD55 MSNs are more
vulnerable to staurosporine-mediated death (10 mM) com-
pared to wt (HD55 = 42.7 ± 2.4, wt = 36.8 ± 1.3, p < 0.05),
while YAC18 MSNs demonstrate neuroprotection and re-
duced cell death compared to wt MSNs (YAC18 = 17.4 ±
0.9, p < 0.001; Figure 6F). Notably, MSNs expressing C6R
mhtt are less susceptible to staurosporine-mediated cell
death than wt (C6R = 20.0 ± 1.2, p < 0.001) and display
a level of cell death similar to MSNs that overexpress neu-
roprotective wt htt (YAC18 versus C6R p > 0.05; Figure 6F)
(ANOVA p < 0.0001).
DISCUSSION
The results presented in this study are consistent with cas-
pase cleavage of mhtt being a crucial event in the patho-
genesis of HD. Here we demonstrate that specific proteo-
lytic cleavage at the caspase-6 site in mhtt is essential for
the HD-related behavioral phenotype and selective neuro-
pathology observed in the YAC128 model of HD. Nuclear
translocation of mhtt fragments coincides with onset of
motor dysfunction in the YAC128 model, supportinga role for a specific nuclear htt fragment in initiating neuro-
nal dysfunction. Furthermore, caspase-6 cleavage of mhtt
influences susceptibility to excitotoxic stress, highlighting
caspase-6-mediated proteolysis of htt and excitotoxicity
as primary mechanisms of striatal neuronal loss in HD.
This evidence suggests that generation of a specific frag-
ment of mhtt in vivo may represent an initiating event in the
pathogenesis of HD.
Numerous in vitro and in vivo studies have demon-
strated that mhtt toxicity occurs via formation of N-termi-
nal htt fragments containing expanded CAG repeats (Da-
vies et al., 1997; Hackam et al., 1998; Schilling et al.,
1999). However, not all N-terminal fragments of mhtt dem-
onstrate selective HD-related toxicity. HD cell culture
models that selectively express the exon 1 fragment of
mhtt have been the most extensively studied, yet no pro-
tease described thus far cleaves htt to release a fragment
that corresponds to exon 1. Furthermore, nonselective ex-
pression of a pure expanded CAG tract also results in in
vitro and in vivo toxicity, but this represents general poly-
glutamine toxicity and does not address pathways spe-
cific to HD (Ordway et al., 1997). Additionally, increasing
evidence in vitro and in vivo supports the specific protein
context of the mhtt fragments in initiating toxicity (Yu et al.,
2003; Slow et al., 2005). These observations suggest that
the selective neurodegeneration in HD may be mediated
by a specific N-terminal fragment of mhtt.
Using striatal volume as a primary endpoint, we show
that specific caspase fragments of mhtt are crucial for
neurodegeneration in vivo. Specifically, inhibiting cas-
pase-6 and not caspase-3 cleavage of mhtt protects
against striatal volume and neuronal loss. This result high-
lights the caspase-6 fragment of mhtt (586 aa) as a toxic
fragment. The hypothesis that a specific fragment may un-
derlie disease pathogenesis has been well characterized
in Alzheimer’s disease (AD). Amyloid-b precursor protein
(APP) is also cleaved by proteases, leading to generation
of Ab42 fragments, which play an essential role in initiating
the neurodegeneration observed in AD (Iijima et al., 2004).
Selective downregulation of the toxic Ab42 fragment, and
not Ab40, by therapeutic drugs such as NSAID amelio-
rates the disease phenotype in mouse models of AD
showing differences in toxicity levels of fragments with
only a 2 aa difference (Eriksen et al., 2003).
A significant finding in the C6R mice, in addition to the
absence of neurodegeneration, is the lack of a behavioral
phenotype, indicating that the caspase-6 fragment of mhtt
plays a rate-limiting role in the neuronal dysfunction ob-
served in the YAC128 model. Translocation of htt frag-
ments to the nucleus coincide with onset of motor abnor-
malities in the YAC128 model, suggesting that neuronal
dysfunction may be associated with translocation of this
fragment. In contrast, blocking formation and transloca-
tion of the caspase-6 mhtt fragment in the C6R mice ame-
liorates the behavioral phenotype. Translocation of htt to
the nucleus is associated with increased toxicity in vitro
and neuropathology in vivo (Wheeler et al., 2000; Kim
et al., 2001; Wellington et al., 2002). However, theCell 125, 1179–1191, June 16, 2006 ª2006 Elsevier Inc. 1187
shortstop mouse exhibits widespread diffuse nuclear htt
yet demonstrates no clinical phenotype (Slow et al.,
2005), supporting the hypothesis that it is a specific nu-
clear htt fragment that underlies the neuronal degenera-
tion observed in HD.
Nuclear translocation of htt fragments does occur in the
C6R mice, but it is delayed compared to HD53 mice. The
caspase-6 fragment is not produced in C6R mice; there-
fore, the htt fragments detected in the nuclei of C6R
mice later must result from alternative proteolytic path-
ways, which may include calpains and other caspases.
Calpain activation is detected in the 3-NP model of HD,
and this was associated with calpain-dependent cleavage
of htt (Bizat et al., 2003). Furthermore, selective calpain in-
hibition reduced the size of the striatal lesion and abol-
ished 3-NP-induced DNA fragmentation in striatal cells.
Interestingly, in rats, intracerebroventricular infusion of
zVAD, a broad-spectrum caspase inhibitor, significantly
reduced 3NP-induced striatal degeneration and de-
creased the 3NP-induced activation of calpain (Bizat
et al., 2005). There may be sequential pathways of htt pro-
teolysis, and further cleavage of caspase-derived htt frag-
ments by calpains may generate fragments capable of
passive diffusion into the nucleus (Kim et al., 2001). How-
ever, the results of our study place cleavage of htt at the
caspase-6 site as a rate-limiting proteolytic event in the
pathogenesis of HD, as blocking htt cleavage at this site
is sufficient to provide in vitro and in vivo protection from
a variety of toxic insults.
Excitotoxicity has been implicated as fundamental in
the earliest stages of HD (Beal et al., 1986; Albin et al.,
1990, 1992; Zeron et al., 2002). Significantly increased
NMDAR-mediated current density and/or enhanced sus-
ceptibility to glutamate and NMDA have been observed
in numerous HD mouse models (Levine et al., 1999; Zeron
et al., 2002; Shehadeh et al., 2005; Graham et al., 2005).
Furthermore, striatal glutamate receptors show dispro-
portionate loss in HD human brain (Albin et al., 1992),
and excitotoxic lesions from glutamate intrastriatal injec-
tions in mice and primates closely resemble the neuropa-
thology in HD (Beal et al., 1986).
In contrast, overexpression of wild-type htt has been
shown to be neuroprotective in a number of stress-
induced model systems, including NMDAR-mediated ex-
citotoxicity, QA-induced neurotoxicity, and ischemia
(Zhang et al., 2003; Leavitt et al., 2006). While the underly-
ing mechanism by which htt mediates neuroprotection is
currently unclear, htt has been shown to interact with cas-
pase-2, suggesting a possible role for htt as a caspase
inhibitor (Hermel et al., 2004). It has been demonstrated
that the neuroprotective role of htt lies upstream of cas-
pase-3 and may take place at the level of initiator caspases
(Rigamonti et al., 2001).
In this study, we demonstrate that caspase-6- but not
caspase-3-resistant mhtt protects neurons from excito-
toxic stress, supporting the hypothesis that not all mhtt
fragments contribute to excitotoxic death. It has been pre-
viously demonstrated in vitro using transfected HEK2931188 Cell 125, 1179–1191, June 16, 2006 ª2006 Elsevier Inc.cells that enhanced NMDAR-mediated cell death is not
observed with a 548 aa N-terminal fragment of mhtt similar
to the caspase-3 fragment of htt (Zeron et al., 2001). In ad-
dition, truncated mouse models including R6, N171, and
shortstop demonstrate resistance to QA-induced excito-
toxicity (Hansson et al., 1999; Jarabek et al., 2004; Slow
et al., 2005). Thus, no excitotoxicity is observed in vivo
with expression of 97, 117, or 171 aa mhtt fragments.
These findings suggest that caspase-6 cleavage of mhtt
selectively mediates susceptibility to excitotoxic stress
via a specific mhtt fragment.
In this study, we demonstrate that a specific mhtt frag-
ment contributes to the selective striatal neurodegenera-
tion observed in the YAC128 model. Furthermore, the pro-
tection observed from expression of C6R mhtt is
independent of the particular apoptosis-inducing signal,
as protection from staurosporine is also observed. While
all of the evidence supports the 586 aa site in htt as a cas-
pase-6 site in vitro, it cannot be definitively excluded that
in vivo other proteases may cleave htt at this site. Activa-
tion of caspase-6 may also contribute to pathogenesis via
cleavage and degradation of key survival proteins such as
CBP, Akt, and NF-kb. In addition, it cannot be ruled out
that altering the 586 aa site in mhtt has affected conforma-
tional changes, stability, and/or clearance of full-length
mhtt. Precisely how the caspase-6 mhtt fragment leads
to the selective neuronal degeneration and behavioral ab-
normalities seen in this YAC model is unclear. This could
be mediated either directly by the toxicity of this particular
fragment itself or via activation of other pathways crucial
to the pathogenesis of HD.
Our in vivo and in vitro characterization of caspase-
resistant mhtt provides substantial support for the hypoth-
esis that cleavage at the caspase-6 site in mhtt represents
a crucial rate-limiting event in the pathogenesis of HD.
Furthermore, we demonstrate a strong correlation be-
tween excitotoxicity and the disease phenotype, suggest-
ing links between proteolysis of htt and excitotoxicity. Our
study highlights the importance of preventing cleavage of
htt at this site and also reinforces the importance of mod-
ulating excitotoxicity as a potential therapeutic approach
for HD.
EXPERIMENTAL PROCEDURES
Generation of YAC Transgenic Mice
Verified CR YACs were purified by pulsed-field electrophoresis and mi-
croinjected into FVB/N oocytes. PCR of the CAG repeat was as de-
scribed (Graham et al., 2005).
Real-Time Quantitative RT-PCR
Total RNA was extracted from mouse cortex with RNeasy Protect Mini
Kit (QIAGEN). First-strand cDNA was prepared using SuperScript
First-Strand Synthesis System (Invitrogen). Human-specific HD and
mouse-specific b-actin primers and RT-PCR were as described (Gra-
ham et al., 2005). Amplification of mouse b-actin was performed to
standardize the amount of sample RNA added to the reaction. HD
gene-expression levels were measured using the RQ Study Add On
software (ABI).
Protein Analysis and Western Blotting
Protein was prepared as described (Graham et al., 2005). One hundred
micrograms was run on 7.5% or 10% low bis-polyacrylamide gels;
transferred to PVDF membranes; and then probed with BKP1 (Hodg-
son et al., 1999), 1C2 (MAB1574, Chemicon), or Actin (Sigma). Densi-
tometric values from scanned Western blots were obtained using
Quantity One (Bio-Rad).
Ex Vivo Confirmation of Caspase-Resistant htt
Whole mouse brain protein lysates were prepared as described (Gra-
ham et al., 2005) without zVAD added in the lysis buffer. Ex vivo cleav-
age of htt was as per Wellington et al. (1998). Protein was transferred
onto PVDF membranes (Millipore) and then probed with BKP1.
Rescue of Embryonic Lethality of htt-Deficient Mice
FVB/N mice expressing the HD or CR YAC were crossed to mice
heterozygous for the murine HD gene. Tail DNA was screened for the
YAC and genotyped for the null allele as described (Hodgson et al.,
1996). Genotypes were analyzed by chi-square analysis (GraphPad
Prism 4.0).
Quantitative Neuropathological Analysis
All quantitative analysis was done blind to genotype. Mice were
weighed, terminally anesthetized by intraperitoneal injection of 2.5%
avertin, and perfused with 3% paraformaldehyde/0.15% glutaralde-
hyde in PBS. The brains were immersed in 3% paraformaldehyde for
24 hr at 4ºC then removed and stored in PBS. Mouse brains were
cut using a vibratome, and coronal sections (25 mm) spaced 200 mm
apart throughout the striatum were stained with NeuN (Chemicon) as
described previously (Slow et al., 2003). Striatal volume and neuronal
counts were assessed as described previously (Slow et al., 2003).
Behavior
Wild-type, HD53, and C6R7 mice were group housed in microisolator
cages with a normal light-dark cycle. Mice were randomly coded and
the tester was blind to the genotypes. Rotarod analysis was as de-
scribed (Van Raamsdonk et al., 2005c). Open-field analysis was con-
ducted in the dark in an automated open-field activity apparatus
(San Diego Instruments). Measurements were calculated by accompa-
nying software, Photobeam Analysis System (San Diego Instruments).
Assessment of htt552 and Nuclear Huntingtin
Perfused brain sections were immunoassayed with htt552 or EM48 as
described (Wellington et al., 2002; Gutekunst et al., 1999). Biotinylated
secondary antibodies (Vector) were used at 1:200 prior to signal
amplification with an ABC Elite kit (Vector) and detection with DAB
(Pierce). Photographs were taken on a light microscope using an
1003 objective.
NMDAR-Mediated Excitotoxicity
Pooled cultures (6–10 pups) of primary MSNs were prepared from
newborn pups (P0–P1) as described (Shehadeh et al., 2005). Cultures
were maintained in vitro for 9–10 days prior to treatment with balanced
salt solution, 500 mM NMDA (Sigma), or 500 mM NMDA + 20 mM MK801
and assessed for apoptotic cell death as described (Shehadeh et al.,
2005). Exposure of MSNs to staurosporine was for 24 hr using 100
nM and 10 mM doses. For each experiment (n = 3), all treatments
were done blind and in triplicate, and a minimum of 1000 cells were
counted.
Quinolinic-Acid Injections
QA (Sigma) was dissolved into 0.1 M PBS. Mice were anesthetized
with isofluorane and received bilateral intrastriatal injections of 4 nM
quinolinic acid. Seven days postinjection, mice were terminally anes-
thetized, perfused, and analyzed as described (Zeron et al., 2002).Statistical Analyses
All statistical analyses were done using one-way or repeated-mea-
sures ANOVA (in cases of significant effect of genotype, post hoc com-
parisons between genotypes were performed using Tukey’s test)
or the unpaired two-tailed Student’s t test. p values, SEM, means,
SD, and chi-square analysis were calculated using Graphpad Prism
version 4.0.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at
http://www.cell.com/cgi/content/full/125/6/1179/DC1/.
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